Condition: Colorectal Cancer (CRC) · Advanced Adenomas (AA) · Sponsor: Universal Diagnostics
A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.
This description comes directly from the study's public registry record.
Antonio Jesus Merino Calvo · (+34)674945571 · antonio.merino@universaldx.com
Always discuss trial participation with your own doctor first.
| Precision Recearch Institute | Chula Vista, California, United States | Completed |
| Precision Research Institute | San Diego, California, United States | Completed |
| Medical Associates Research Group | San Diego, California, United States | Completed |
| Clinical Research of California | Walnut Creek, California, United States | Completed |
| Center for Gastrointestinal Disorders | Hollywood, Florida, United States | Completed |
| Lakeland Regional Cancer Center | Lakeland, Florida, United States | Recruiting |
| Springfield Clinic | Springfield, Illinois, United States | Recruiting |
| Ochsner Clinic | New Orleans, Louisiana, United States | Completed |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Completed |
| Mid Hudson Medical Research | New Windsor, New York, United States | Recruiting |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | Completed |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04792684